Recent Updates
Recently added Catalysts
KLRS Positive Sentiment

Kalaris Appoints Laurie Keating to Board of Directors

Monday, July 6, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Kalaris Therapeutics has appointed Laurie Keating to its Board of Directors. Keating is a highly experienced biotechnology executive, and her expertise is expected to support Kalaris in its upcoming growth phase. This strategic move reflects Kalaris's commitment to advancing its clinical-stage biopharmaceutical initiatives.
Price reaction · baseline $4.65 (2026-07-06 close) · hit after-hours · clean, no other KLRS news in the window
day 0 close · peak
+3.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • Appointment of Laurie Keating brings extensive experience.
  • Keating's expertise will aid Kalaris in growth.
  • Kalaris is entering a new phase of development.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~25 mo
Minimal dilution risk
Lead asset
Multivirus-specific T cells Dose Level 1
Phase 1 · Viral Infection

Full Press Release Details

Highly experienced biotechnology executive and board member will assist Kalaris in achieving its next phase of growth BERKELEY HEIGHTS, N.J., July 06, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the

Frequently Asked Questions

Who has been appointed to Kalaris's Board of Directors?

Laurie Keating has been appointed to the Board of Directors of Kalaris.

What is Laurie Keating's background?

Laurie Keating is a highly experienced biotechnology executive.

What will Keating's role involve at Kalaris?

Keating will assist Kalaris in achieving its next phase of growth.

What type of company is Kalaris Therapeutics?

Kalaris is a clinical-stage biopharmaceutical company.

ShareAdd on Google
Tags: KLRS Viatris Investor Conferences Healthcare Kalaris Laurie Keating Board of Directors biopharmaceutical clinical-stage
Last updated: Jul 6, 2026

Biotech snapshot

Cash runway
$94M liquidity · $4M/mo burn
~25 mo
Minimal dilution risk
Lead asset
Multivirus-specific T cells Dose Level 1Phase 1
Viral Infection →